Skip to main content
Article
Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma
International Journal of Hematology (2019)
  • Jose D. Sandoval-Sus, Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, H. Lee Moffitt Cancer Center, Pembroke Pines, USA
  • Amanda Brahim, Department of Pharmacy, Memorial Healthcare System, Pembroke Pines, USA
  • Alina Khan, Department of Pharmacy, Memorial Healthcare System, Pembroke Pines, USA
  • Barbara Raphael, Department of Diagnostic Radiology, Memorial Healthcare System, Pembroke Pines, USA
  • Ali Ansari-Lari, Division of Hematopathology, Department of Anatomic and Clinical Pathology, Memorial Healthcare System, Hollywood, USA
  • Marco Ruiz, Department of Malignant Hematology and Cellular Therapy at Memorial Healthcare System, H. Lee Moffitt Cancer Center, Pembroke Pines, USA
Publication Date
May 1, 2019
DOI
10.1007/s12185-019-02592-3
Citation Information
Jose D. Sandoval-Sus, Amanda Brahim, Alina Khan, Barbara Raphael, et al.. "Brentuximab vedotin as frontline treatment for HIV-related extracavitary primary effusion lymphoma" International Journal of Hematology Vol. 109 Iss. 5 (2019) p. 622 - 626
Available at: http://works.bepress.com/marco-ruiz/2/